Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases — NextGen-SE  

Cognitive Decline Clinical Trial

Official title: Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases

Status Recruiting

Clinical Trial Summary

In the study, NextGen SE are on-hand a cohort comprising each 50 pediatric and 50 adult patients, and in which there are an unclear movement disorder or an unclear cognitive disorder, examines the following questions : Primary: - Number of diagnoses made by NGS Secondary: 1. restriction of the quality of life by unclear disease 2. Cost of not purposeful preliminary diagnostics ( beyond the minimal diagnostic data set ) 3. Impact of the diagnosis to therapy and follow-up examinations 4. Time to diagnosis

Clinical Trial Description

In the study NextGen SE (single-center, prospective, open diagnostic study) are on-hand a cohort comprising each 50 pediatric and 50 adult patients, and in which there are an unclear movement disorder or an unclear cognitive disorder, examines the following questions: Primary: - Number of diagnoses made by next-generation sequencing (NGS) Secondary: 1. Restriction of the quality of life by unclear disease 2. Cost of not purposeful preliminary diagnostics (beyond the minimal diagnostic data of the diagnosis to therapy and follow-up examinations 3. Time to diagnosis ;

Related Conditions & MeSH terms

• Cognitive Decline
• Cognitive Dysfunction
• Movement Disorder
• Movement Disorders
• Rare Diseases

• NCT number: NCT02588638
• Study type: Observational [Patient Registry]
• Source: University Hospital Tuebingen
• Contact: Ludger Schöls, Prof. Dr.
• Phone: +49 7071 29-80445
• Email: ludger.schoels@uni-tuebingen.de
• Status: Recruiting
• Start date: December 2015
• Completion date: September 2023